JP2023526234A5 - - Google Patents
Info
- Publication number
- JP2023526234A5 JP2023526234A5 JP2022568746A JP2022568746A JP2023526234A5 JP 2023526234 A5 JP2023526234 A5 JP 2023526234A5 JP 2022568746 A JP2022568746 A JP 2022568746A JP 2022568746 A JP2022568746 A JP 2022568746A JP 2023526234 A5 JP2023526234 A5 JP 2023526234A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- spacer
- acid sequence
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063023751P | 2020-05-12 | 2020-05-12 | |
| US63/023,751 | 2020-05-12 | ||
| PCT/US2021/032098 WO2021231655A1 (en) | 2020-05-12 | 2021-05-12 | Chimeric antigen receptor spacers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526234A JP2023526234A (ja) | 2023-06-21 |
| JP2023526234A5 true JP2023526234A5 (enExample) | 2024-07-31 |
Family
ID=76250478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568746A Pending JP2023526234A (ja) | 2020-05-12 | 2021-05-12 | キメラ抗原受容体スペーサー |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210380658A1 (enExample) |
| EP (1) | EP4149968A1 (enExample) |
| JP (1) | JP2023526234A (enExample) |
| KR (1) | KR20230022411A (enExample) |
| CN (1) | CN116096739A (enExample) |
| AU (1) | AU2021270299A1 (enExample) |
| BR (1) | BR112022022953A2 (enExample) |
| CA (2) | CA3157427A1 (enExample) |
| IL (1) | IL298114A (enExample) |
| MX (1) | MX2022014203A (enExample) |
| WO (1) | WO2021231655A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4121447A1 (en) | 2020-03-20 | 2023-01-25 | Lyell Immunopharma, Inc. | Novel recombinant cell surface markers |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| US20250011399A1 (en) * | 2021-11-10 | 2025-01-09 | Outpace Bio, Inc. | Chimeric antigen receptors |
| CN115724986B (zh) * | 2022-07-11 | 2024-07-19 | 惠和生物技术(上海)有限公司 | 三特异性抗体及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| CA2531118C (en) | 2003-07-01 | 2013-01-08 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| EP1786918A4 (en) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | NEW BISPECIFIC ANTIBODY TETRAVALENT |
| KR20140053410A (ko) | 2005-08-19 | 2014-05-07 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| US20100047171A1 (en) * | 2006-01-24 | 2010-02-25 | Roland Beckmann | Fusion Proteins That Contain Natural Junctions |
| US9316646B2 (en) | 2009-04-23 | 2016-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ROR1 antibodies |
| EP2646469B1 (en) | 2010-12-01 | 2017-11-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Chimeric rabbit/human ror1 antibodies |
| GB201203071D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| LT2884999T (lt) * | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| CN107074957B (zh) * | 2014-01-13 | 2021-05-07 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| US10752684B2 (en) * | 2014-07-29 | 2020-08-25 | Cellectis | ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy |
| US20160208018A1 (en) * | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| GB201803079D0 (en) * | 2018-02-26 | 2018-04-11 | Autolus Ltd | Cell |
| JP7438123B2 (ja) * | 2018-03-14 | 2024-02-26 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体 |
| EP3774866A1 (en) * | 2018-04-13 | 2021-02-17 | Ludwig Institute for Cancer Research Ltd | Heterodimeric inactivatable chimeric antigen receptors |
| BR112020022185A2 (pt) * | 2018-05-03 | 2021-02-02 | Juno Therapeutics Inc | terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase |
| EP3807317A4 (en) * | 2018-06-15 | 2022-03-30 | The Regents of University of California | CHIMERIC FUSION FRAGMENT ANTIGEN RECEPTORS AND USES THEREOF |
| WO2020167957A1 (en) * | 2019-02-12 | 2020-08-20 | Board Of Regents, The University Of Texas System | High affinity engineered t-cell receptors targeting cmv infected cells |
| AU2020295715A1 (en) * | 2019-06-19 | 2022-02-17 | Julius-Maximilians-Universität Würzburg | Ultramodular IgG3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design |
-
2021
- 2021-05-12 MX MX2022014203A patent/MX2022014203A/es unknown
- 2021-05-12 US US17/318,996 patent/US20210380658A1/en not_active Abandoned
- 2021-05-12 CA CA3157427A patent/CA3157427A1/en active Pending
- 2021-05-12 EP EP21729739.9A patent/EP4149968A1/en active Pending
- 2021-05-12 JP JP2022568746A patent/JP2023526234A/ja active Pending
- 2021-05-12 BR BR112022022953A patent/BR112022022953A2/pt unknown
- 2021-05-12 AU AU2021270299A patent/AU2021270299A1/en active Pending
- 2021-05-12 CN CN202180048789.6A patent/CN116096739A/zh active Pending
- 2021-05-12 IL IL298114A patent/IL298114A/en unknown
- 2021-05-12 KR KR1020227043445A patent/KR20230022411A/ko active Pending
- 2021-05-12 CA CA3265893A patent/CA3265893A1/en active Pending
- 2021-05-12 WO PCT/US2021/032098 patent/WO2021231655A1/en not_active Ceased
-
2025
- 2025-09-08 US US19/322,325 patent/US20260098075A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11180553B2 (en) | Chimeric antigen receptor | |
| CN112771167B (zh) | 表达有趋化因子的细胞及用途 | |
| JP2025020221A (ja) | ＮＫｐ３０に結合する抗体分子およびその使用 | |
| CN110616191B (zh) | 共刺激配体联合的car t疗法 | |
| JP2025500522A5 (enExample) | ||
| US11332513B2 (en) | Chimeric antigen receptors having GITR intracellular domain as co-stimulatory domain | |
| KR20180057720A (ko) | 다가 Fv 항체 | |
| JP2015527070A5 (enExample) | ||
| IL294518A (en) | Bcma-directed cellular immunotherapy compositions and methods | |
| TW201841944A (zh) | 4-1bbl變異體及包含其之融合蛋白 | |
| JP2024525727A5 (enExample) | ||
| US20220133792A1 (en) | Signaling platforms for chimeric antigen receptor t cells | |
| JP2024510900A5 (enExample) | ||
| CN110423757B (zh) | 一种工程化核酸、t细胞及其应用和产生方法 | |
| JP2025536940A (ja) | 新規ｃｄ１９バインダー、それを含むｃａｒ－ｔ構造体、およびその使用方法 | |
| WO2021057906A1 (zh) | 表达il-15的免疫效应细胞 | |
| WO2022057941A1 (zh) | 表达il-7r结合蛋白的免疫效应细胞 | |
| JP2025535365A (ja) | Ｉｌ１８と結合した新規ｃｄ１９結合体を含むｃａｒ－ｔ構築物およびその使用方法 | |
| WO2019150133A1 (en) | Chimeric receptor | |
| CN116096739A (zh) | 嵌合抗原受体间隔物 | |
| WO2023051361A1 (zh) | 工程化免疫细胞及其用途 | |
| CN115073606A (zh) | 一种靶向表达cldn 18.2的细胞的人源化嵌合抗原受体 | |
| WO2020162452A1 (ja) | ＣＡＲライブラリおよびｓｃＦｖの製造方法 | |
| CN110540997A (zh) | 靶向bcma嵌合抗原受体、核酸序列、载体及应用 | |
| CN120322459A (zh) | 多特异性蛋白及相关方法 |